SageView Advisory Group’s Moderna MRNA Stock Holding History

SageView Advisory Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,364	Closed	-$40.2K	–	1740
2025 Q4	$40.2K	Buy	+1,364	New	+$37.1K	﹤0.01%	1165

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SageView Advisory Group's MRNA Position: Q1 2026 in Review

SageView Advisory Group sold out of Moderna (MRNA) in Q1 2026, closing a stake of 1,364 shares — an estimated $40.2K sold.

SageView Advisory Group first reported a position in MRNA in Q4 2025 and held it in 1 quarter. The position peaked at $40.2K in Q4 2025. 726 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

SageView Advisory Group reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 1,364 Moderna shares in Q1 2026, an estimated $40.2K.
SageView Advisory Group first reported a position in Moderna in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Moderna position peaked at $40.2K in Q4 2025.
726 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.